BW-1010

The purpose of this clinical trial is to evaluate the safety and immunogenicity of BW-1010.
BW-1010 is a nanoemulsion adjuvanted recombinant protein (rPA) that would protect against fatal outcome resulting from exposure to anthrax.
The vaccine will be administered intranasally (IN) to healthy adults, age 18 - 49.
The study will be conducted in 84 volunteers in one center in the United States.
The study will compare 2 different dose levels of rPA (50µg and 100µg rPA), and 2 different administration methods (a sprayer and dropper) with a negative control (saline) and a positive control (the injectable BioThrax licensed vaccine).
The vaccines and negative controls will be administered in 2 IN doses (4 weeks apart). The positive control will be 3 subcutaneous doses, 2 weeks apart. All volunteers will be observed for 1 year after the last dose.
Immunological outcome studied will be from the serum, blood cells and nasal washes.